X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (52) 52
male (43) 43
index medicus (41) 41
middle aged (41) 41
female (37) 37
adult (35) 35
aged (33) 33
hematology (20) 20
life sciences (18) 18
aged, 80 and over (17) 17
abridged index medicus (15) 15
oncology (13) 13
cancer (12) 12
prognosis (12) 12
treatment outcome (11) 11
adolescent (10) 10
bortezomib (10) 10
prospective studies (10) 10
survival (10) 10
steklov problem (9) 9
antineoplastic combined chemotherapy protocols - therapeutic use (8) 8
chemotherapy (8) 8
cyclophosphamide - administration & dosage (8) 8
dexamethasone (8) 8
mathematics (8) 8
radiology, nuclear medicine & medical imaging (8) 8
retrospective studies (8) 8
rituximab (8) 8
therapy (8) 8
[ sdv.can ] life sciences [q-bio]/cancer (7) 7
[sdv.can]life sciences [q-bio]/cancer (7) 7
antineoplastic combined chemotherapy protocols - adverse effects (7) 7
diagnosis (7) 7
lenalidomide (7) 7
melphalan (7) 7
stem-cell transplantation (7) 7
[ sdv ] life sciences [q-bio] (6) 6
disease-free survival (6) 6
doxorubicin - administration & dosage (6) 6
elderly-patients (6) 6
multiple myeloma (6) 6
multiple myeloma - drug therapy (6) 6
multiple-myeloma (6) 6
non-hodgkins-lymphoma (6) 6
p-laplacian (6) 6
patients (6) 6
prednisone - administration & dosage (6) 6
survival rate (6) 6
translocation, genetic (6) 6
tunisia (6) 6
[sdv]life sciences [q-bio] (5) 5
antineoplastic combined chemotherapy protocols - administration & dosage (5) 5
b-cell lymphoma (5) 5
care and treatment (5) 5
follow-up (5) 5
follow-up studies (5) 5
hemic and lymphatic diseases (5) 5
neoplasm staging (5) 5
prednisone (5) 5
survival analysis (5) 5
time factors (5) 5
young adult (5) 5
102 (4) 4
amyloidosis (4) 4
animals (4) 4
antibodies, monoclonal, murine-derived - administration & dosage (4) 4
bone marrow (4) 4
bone marrow - pathology (4) 4
bortezomib - administration & dosage (4) 4
clinical trials (4) 4
cyclophosphamide (4) 4
dexamethasone - administration & dosage (4) 4
disease progression (4) 4
efficacy (4) 4
expression (4) 4
hodgkin disease - pathology (4) 4
infections (4) 4
lymphoid neoplasia (4) 4
lymphoma, large b-cell, diffuse - mortality (4) 4
lymphoma, large b-cell, diffuse - pathology (4) 4
mountain pass theorem (4) 4
multiple myeloma - diagnosis (4) 4
multiple myeloma - genetics (4) 4
multiple myeloma - mortality (4) 4
positron-emission-tomography (4) 4
risk factors (4) 4
sobolev trace embedding (4) 4
transplantation (4) 4
transplantation, autologous (4) 4
weights (4) 4
analysis (3) 3
antineoplastic agents - therapeutic use (3) 3
bone-marrow angiogenesis (3) 3
cardiac patients (3) 3
carfilzomib (3) 3
combined modality therapy (3) 3
contrast media (3) 3
criteria (3) 3
cyclophosphamide - adverse effects (3) 3
dexamethasone - adverse effects (3) 3
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 04/2017, Volume 376, Issue 14, pp. 1311 - 1320
In this trial, 700 patients with myeloma were randomly assigned to receive RVD therapy (lenalidomide, bortezomib, and dexamethasone) with or without autologous... 
DIAGNOSED MULTIPLE-MYELOMA | MEDICINE, GENERAL & INTERNAL | PHASE-III | AUTOLOGOUS TRANSPLANTATION | DARATUMUMAB MONOTHERAPY | INITIAL TREATMENT | FOLLOW-UP | PREDNISONE PLUS THALIDOMIDE | RANDOMIZED CONTROLLED-TRIAL | STEM-CELL TRANSPLANTATION | ELDERLY-PATIENTS | Humans | Middle Aged | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dexamethasone - adverse effects | Induction Chemotherapy | Male | Transplantation, Autologous | Stem Cell Transplantation | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Adult | Female | Maintenance Chemotherapy | Thalidomide - adverse effects | Dexamethasone - administration & dosage | Lenalidomide | Kaplan-Meier Estimate | Combined Modality Therapy | Thalidomide - administration & dosage | Disease-Free Survival | Bortezomib - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Bortezomib - adverse effects | Aged | Usage | Care and treatment | Bortezomib | Dexamethasone | Patient outcomes | Multiple myeloma | Transplantation of organs, tissues, etc | Dosage and administration | Autografts | Gastrointestinal tract diseases | Minimal residual disease | Stem cell transplantation | Peripheral neuropathy | Patients | Chemotherapy | Melphalan | Thromboembolism | Neutropenia | Life Sciences | Cancer
Journal Article
Blood, ISSN 0006-4971, 05/2016, Volume 127, Issue 21, pp. 2569 - 2574
Journal Article
AIP Conference Proceedings, ISSN 0094-243X, 12/2019, Volume 2183, Issue 1
Using Ljusternik-Schnirelmann principle and a new variational technic we prove that the following Steklov eigenvalue problem has infinitely many positive... 
Eigenvalues | Smooth boundaries | Eigen values
Journal Article
Journal Article
American Journal of Hematology, ISSN 0361-8609, 06/2019, Volume 94, Issue 6, pp. 635 - 640
The risk of venous thromboembolism (VTE) is higher in myeloma patients receiving immunomodulatory compounds. A VTE prophylaxis using low‐molecular‐weight... 
MULTIPLE-MYELOMA | ENOXAPARIN | DEXAMETHASONE | VENOUS THROMBOEMBOLISM | THROMBOSIS | LENALIDOMIDE | THROMBOPROPHYLAXIS | THALIDOMIDE | HEMATOLOGY
Journal Article
The Lancet, ISSN 0140-6736, 07/2019, Volume 394, Issue 10192, pp. 29 - 38
Journal Article
Haematologica, ISSN 0390-6078, 07/2013, Volume 98, Issue 7, pp. 1107 - 1114
Journal Article
Mayo Clinic Proceedings, ISSN 0025-6196, 06/2019, Volume 94, Issue 6, pp. 961 - 975
Journal Article
Haematologica, ISSN 0390-6078, 08/2011, Volume 96, Issue 8, pp. 1136 - 1143
Journal Article